Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

Table 1 HPD rates in different clinical studies

Type of cancer	N° of patients	HPD rate (%)	Reference
Different types of cancer	131	9	[24]
NSCLC	335	13.1	[25]
Gastric cancer	36	11.1	[26]
Different types of cancer	182	6.6	[27]
NSCLC	406	13.8	[28]
NSCLC	152	25.7	[29]
HNSCC	34	29	[30]
Different types of cancer	155	4	[31]

ISSN: 1756-9966